MorphoSys | Jotup

Incyte Gains Exclusive Global Development and Commercialization Rights to Tafasitamab (Monjuvi®)

Retrieved on:

星期一, 二月 5, 2024

Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, MorphoSys, DLBCL, FC, Tafasitamab, Immunotherapy, Pharmaceutical industry

Incyte (Nasdaq:INCY) announced it has entered into an asset purchase agreement with MorphoSys AG (FSE: MOR; NASDAQ: MOR) which gives Incyte exclusive global rights for tafasitamab, a humanized Fc-modified CD19-targeting immunotherapy marketed in the U.S. as Monjuvi® (tafasitamab-cxix) and outside of the U.S. as Minjuvi® (tafasitamab).

Key Points:

Incyte (Nasdaq:INCY) announced it has entered into an asset purchase agreement with MorphoSys AG (FSE: MOR; NASDAQ: MOR) which gives Incyte exclusive global rights for tafasitamab, a humanized Fc-modified CD19-targeting immunotherapy marketed in the U.S. as Monjuvi® (tafasitamab-cxix) and outside of the U.S. as Minjuvi® (tafasitamab).
“This new agreement with MorphoSys provides Incyte with exclusive global rights to tafasitamab and full control over its development and commercialization, allowing us to realize significant operating efficiencies and cost synergies,” said Hervé Hoppenot, Chief Executive Officer, Incyte.
In the previous agreement , MorphoSys and Incyte were collaborating and sharing costs for the clinical development and commercialization of tafasitamab in the U.S.; Incyte had exclusive rights outside of the U.S.
Under the terms of the new agreement, MorphoSys will receive a payment of $25 million from Incyte and Incyte will gain global development and commercialization rights for tafasitamab.

HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization

Retrieved on:

星期二, 一月 16, 2024

Bristol Myers Squibb, Partnership, Standard of care, Heidelberg University, Arenavirus, Head, MorphoSys, Drug development, Doctor of Philosophy, Master of Science, Max Planck Society, Management

Dr. Winderlich has rich experience leading multiple candidates through the drug development process to product approval in the United States and in Europe.

Key Points:

Dr. Winderlich has rich experience leading multiple candidates through the drug development process to product approval in the United States and in Europe.
“We are pleased to bring our search for a capable clinical development leader to such a swift, successful resolution and welcome Mark to the team,” said Joern Aldag, Chief Executive Officer at HOOKIPA.
“Mark is a tremendous talent with rich experience across the drug development lifecycle.
Prior to Evotec, Dr. Winderlich spent more than 12 years in drug development at MorphoSys AG across various roles of increasing responsibility.

Biodexa Appoints Ann Merchant to the Board of Directors

Retrieved on:

星期五, 十二月 29, 2023

Henley Business School, Type 1, Amgen, Georgetown University, Merchant, MBA, MorphoSys, Head

Since 2018, Ann Merchant has served as Vice President for MorphoSys, and currently as Head of Global Supply Chain and External Operations.

Key Points:

Since 2018, Ann Merchant has served as Vice President for MorphoSys, and currently as Head of Global Supply Chain and External Operations.
Merchant is a U.S citizen and holds a Bachelor of Science in Languages from Georgetown University and an MBA from the Henley Business School.
Commenting, Dr Stephen Parker, Chairman Biodexa, said: “I am very pleased to welcome Ann to the Board.
With her broad experience of operations on an international scale she will bring a different perspective and complement the existing skillset of the Board”.

EQS-News: MorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study

Retrieved on:

星期六, 十二月 30, 2023

Spleen, Patient, EST, Food, TNF, Survival, Constipation, Bone marrow, BET, Prognosis, Diarrhea, Plasma, Anemia, Fatigue, Headache, Disease, Nausea, GMT, Ruxolitinib, Thrombocytopenia, Weakness, Dizziness, ASH, JAK, MorphoSys, COVID-19, Periodic breathing, European Medicines Agency, IL-6, PST, Development, Fibrosis, Cough, Dysgeusia, FACP

Average hemoglobin levels were greater in patients receiving pelabresib and ruxolitinib than in those receiving placebo plus ruxolitinib, starting at week 9 and continuing to week 24.

Key Points:

Average hemoglobin levels were greater in patients receiving pelabresib and ruxolitinib than in those receiving placebo plus ruxolitinib, starting at week 9 and continuing to week 24.
Increased cytokine levels are associated with all four disease hallmarks; increased IL-8 levels are also associated with worse survival outcomes.
Discontinuation rates due to adverse events were 10.7% with pelabresib and ruxolitinib and 6.5% with placebo plus ruxolitinib.
“The four hallmarks of myelofibrosis – enlarged spleen, anemia, bone marrow fibrosis and disease-associated symptoms – have a strong impact on a patient’s life.

Tome Biosciences Launches with Over $200 Million in Funding to Advance Programmable Genomic Integration Platform

Retrieved on:

星期二, 十二月 12, 2023

Backed by leading biotech investors Andreessen Horowitz, ARCH, GV, Longwood, Polaris and others

Key Points:

Backed by leading biotech investors Andreessen Horowitz, ARCH, GV, Longwood, Polaris and others
WATERTOWN, Mass., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Tome Biosciences , Inc., the programmable genomic integration company, has launched to usher in a new era of genomic medicines based on programmable genomic integration (PGI).
“PGI represents the maturation of editing technologies, breaking current barriers in genomic medicines discovery,” said Rahul Kakkar, MD, President and Chief Executive Officer.
“PGI is revolutionary in that we can finally reprogram the human genome with an elegance and efficiency previously unimaginable.
Tome has an exclusive license to the core PASTE technology, which includes granted US patent numbers 11,572,556, 11,827,881 and 11,834,658.

MorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study

Retrieved on:

星期一, 十二月 11, 2023

Average hemoglobin levels were greater in patients receiving pelabresib and ruxolitinib than in those receiving placebo plus ruxolitinib, starting at week 9 and continuing to week 24.

Key Points:

Average hemoglobin levels were greater in patients receiving pelabresib and ruxolitinib than in those receiving placebo plus ruxolitinib, starting at week 9 and continuing to week 24.
Increased cytokine levels are associated with all four disease hallmarks; increased IL-8 levels are also associated with worse survival outcomes.
Discontinuation rates due to adverse events were 10.7% with pelabresib and ruxolitinib and 6.5% with placebo plus ruxolitinib.
“The four hallmarks of myelofibrosis – enlarged spleen, anemia, bone marrow fibrosis and disease-associated symptoms – have a strong impact on a patient’s life.

MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction

Retrieved on:

星期一, 十一月 20, 2023

Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, FSE, Ruxolitinib, MorphoSys, Patient, TSS, BET, JAK, Pharmaceutical industry, Medical imaging

MANIFEST-2 met its primary endpoint, as the combination therapy demonstrated a statistically significant and clinically meaningful improvement in the proportion of patients achieving at least a 35% reduction in spleen volume (SVR35) at week 24.

Key Points:

MANIFEST-2 met its primary endpoint, as the combination therapy demonstrated a statistically significant and clinically meaningful improvement in the proportion of patients achieving at least a 35% reduction in spleen volume (SVR35) at week 24.
The key secondary endpoints assessing symptom improvement – proportion of patients achieving at least a 50% reduction in total symptom score (TSS50) and absolute change in total symptom score (TSS) from baseline at week 24 – showed a strong positive trend favoring the pelabresib and ruxolitinib combination.
“Importantly, we saw significant symptom improvements for the vast majority of patients in the study.
“The pelabresib and ruxolitinib combination therapy significantly reduced spleen volume – the best prognostic indicator we have at our disposal for long-term myelofibrosis patient outcomes.

MorphoSys AG Reports First Nine Months and Third Quarter 2023 Financial Results

Retrieved on:

星期三, 十一月 15, 2023

MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the third quarter and the first nine months of 2023.

Key Points:

MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the third quarter and the first nine months of 2023.
“Sales of Monjuvi remain on track for its approved indication, allowing us to narrow our full-year 2023 guidance target.
Minjuvi royalty revenue of € 1.2 million for sales outside of the U.S. in the third quarter 2023 and € 4.1 million for the first nine months of 2023.
Events After the End of the Third Quarter of 2023:
MorphoSys updated its financial guidance for 2023 financial year on October 25, 2023.

EQS-News: MorphoSys Places New Shares from Cash Capital Increase with Gross Proceeds of Approximately EUR 102.7 Million

Retrieved on:

星期四, 十二月 14, 2023

The 3,423,194 new ordinary bearer shares with no-par value (Stückaktien) (“New Shares”) have been placed with institutional investors at a placement price of EUR 30.00 per new share by way of an accelerated bookbuilding, resulting in gross proceeds of approximately EUR 102.7 million.

Key Points:

The 3,423,194 new ordinary bearer shares with no-par value (Stückaktien) (“New Shares”) have been placed with institutional investors at a placement price of EUR 30.00 per new share by way of an accelerated bookbuilding, resulting in gross proceeds of approximately EUR 102.7 million.
“MorphoSys’ oncology pipeline offers promising value-creating opportunities, with pelabresib, our investigational BET inhibitor, at the forefront,” said Jean-Paul Kress, M.D., Chief Executive Officer of MorphoSys.
“With pelabresib, we have the potential to shift the treatment paradigm in myelofibrosis, a field in dire need of innovation.
The placement price represents a discount of 2.8% compared to the 5-day volume-weighted average price (XETRA) of the Company’s shares.

EQS-News: MorphoSys AG Reports First Nine Months and Third Quarter 2023 Financial Results

Retrieved on:

星期四, 十二月 14, 2023

“With pelabresib, MorphoSys has the potential to meaningfully improve upon current first-line treatments for patients with myelofibrosis.

Key Points:

“With pelabresib, MorphoSys has the potential to meaningfully improve upon current first-line treatments for patients with myelofibrosis.
Minjuvi royalty revenue of € 1.2 million for sales outside of the U.S. in the third quarter 2023 and € 4.1 million for the first nine months of 2023.
Events After the End of the Third Quarter of 2023:
MorphoSys updated its financial guidance for 2023 financial year on October 25, 2023.
Total revenues for the third quarter 2023 were € 63.8 million compared to € 95.8 million for the same period in 2022.